Formulation, Development and Evaluation of Fast Disintegrating Piroxicam Tablets| Stephy Publishers
SOJ Pharmaceutical Sciences - (SOJPS)| Stephy Publishers
Abstract
Piroxicam is a
non-steroidal anti-inflammatory drug used in the treatment of osteo arthritis,
rheumatoid arthritis, ankylosing spondylitis, classified in the Bio
pharmaceutics Drug Classification system as a Class II drug because it has low
solubility and high permeability. It demonstrates a slow and gradual absorption
via the oral route and has a long half-life of elimination, rendering a
prolonged therapeutic action and a delayed onset of anti-inflammatory and
analgesic effect. Thus, an attempt is made to formulate piroxicam fast
disintegrating tablet so that it helps to render faster onset of
anti-inflammatory and analgesic effect. To increase the solubility of piroxicam
solid dispersion method is opted in the present investigation. Study proposes
the use of PVPk30 to prepare solid dispersion of piroxicam and comparison of
its in-vitro dissolution with pure piroxicam. Fast Dissolving tablets can be
prepared by conventional direct compression method using solid dispersion. For
better Hardness, less friability, faster wetting time and less moisture uptake
combination of both MCC and Mannitol are used in the formulation.
Introduction
Fast disintegration drug
delivery system
In this period, fast
disintegrating drug delivery system (FDDDS) began to gain popularity and
acceptance since they can disintegrate/ dissolve quickly in the oral cavity
upon contact with saliva, resulting in solutions or suspensions form of the
administered medicine.Fast disintegrating drug delivery systems (FDDSs) are the
systems which disintegrate even in the absence of additional water and release
the active ingredient quickly. The development of pharmaceutical technology in
past years has presented the development of alternative dosage forms for
patients who may have difficulty in swallowing of conventional tablets. Among
the drug delivery systems, the fast-disintegrating tablets (FDTs) are the more
acceptable form because of its convenience of self-administration, compactness.
Pediatric and geriatric patients, who have difficulty in swallowing,
uncooperative patients, where the traditional tablets and capsules
administration is inconvenient, the fast dissolving/ disintegrating tablets are
perfect alternative. According to European Pharmacopoeia, the FDT disintegrate
in less than three minutes. The basic approach used in development of FDT is
the use of super disintegrants which provide instantaneous disintegration and
thereby releasing the drug in saliva. Taste of the drug is one of the most
important parameters which should be considered for the development of FDTs.
Oral administration of bitter drugs with an acceptable degree of palatability
can be achieved by taste masking approach. The Zydis (Catalent Pharma
Solutions, Somerset, NJ) based on lyophylization technology is the first approved
FDDDS.
Drug Profile
Piroxicam is a
non-steroidal anti-inflammatory drug (NSAID) of the oxicam class and is used to
relieve the symptoms of painful inflammatory conditions like arthritis.
Piroxicam works by preventing the production of endogenous prostaglandins which
are involved in the mediation of pain, stiffness, tenderness and swelling.
To read more #PharmaceuticalSciences
https://www.stephypublishers.com/sojps/fulltext/SOJPS.MS.ID.000501.php
https://www.stephypublishers.com/
Comments
Post a Comment